AR058769A1 - Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. - Google Patents
Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.Info
- Publication number
- AR058769A1 AR058769A1 ARP060105821A ARP060105821A AR058769A1 AR 058769 A1 AR058769 A1 AR 058769A1 AR P060105821 A ARP060105821 A AR P060105821A AR P060105821 A ARP060105821 A AR P060105821A AR 058769 A1 AR058769 A1 AR 058769A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocycle
- amino
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), o una sal, éster o profármaco farmacéuticamente aceptable del mismo en donde: n es 1 o 2; X es CH2, S o CHF; R1 es -N(OH)CHO o -C(O)NH(OH); R2 es alquilo, alquilcicloalquilo o alquilarilo, o R2 representa un grupo cicloalquilo, en donde el C adyacente al grupo carbonilo forma parte del anillo cicloalquilo; R3 es un sustituyente de la formula (2) o (3), o tetrazolilo, 2-perimidinilo o 4-fenilimidazol-2-ilo; en donde Y es NH, O, S, o NR4; A, B, D y E cada uno independientemente se seleccionan de CH, N o CR5; o A y E son CH y B y D se fusionan y forman parte de un anillo arilo o un heterociclo de N con 5 o 6 miembros; R4 es hidroxialquilo, alquilo o heteroalquilo; R5 es haloalquilo, heterociclo opcionalmente sustituido con un grupo alquilo, halogeno, alquilo, amino, ciano, nitro, arilo, alcoxi, haloalcoxi, -CO2R7, -SO2R8, NHC(O)R9 o -NHSO2R9; o dos grupos R5 juntos forman un heterociclo que contiene O de 6 miembros, opcionalmente sustituido con uno o más halogenos y fusionado al anillo de 6 miembros del sustituyentes (1); R6 es amino o alcoxi; R7 es H, alquilo, NHR10, NR10R11 o NH2; R8 es arilo, heterociclo alquilo o amino; R9 es heteroarilo o arilo; y R10 y R11 cada uno es independientemente un grupo alquilo, alquenilo, alquinilo o arilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG200508608-7A SG133452A1 (en) | 2005-12-30 | 2005-12-30 | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058769A1 true AR058769A1 (es) | 2008-02-20 |
Family
ID=37865850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105821A AR058769A1 (es) | 2005-12-30 | 2006-12-27 | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090318445A1 (es) |
EP (1) | EP1973898A1 (es) |
JP (1) | JP2009522232A (es) |
KR (1) | KR20080077655A (es) |
CN (1) | CN101346370A (es) |
AR (1) | AR058769A1 (es) |
AU (1) | AU2006334391A1 (es) |
BR (1) | BRPI0620655A2 (es) |
CA (1) | CA2629148A1 (es) |
PE (1) | PE20071061A1 (es) |
RU (1) | RU2008130925A (es) |
SG (1) | SG133452A1 (es) |
WO (1) | WO2007077186A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20080193411A1 (en) * | 2006-11-21 | 2008-08-14 | Genelabs Technologies, Inc. | Anti-viral Compounds |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
CA2715400A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | Heterocyclic derivatives as hepatitis c virus inhibitors |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2332562A3 (en) * | 2009-04-09 | 2011-09-28 | Universität zu Köln | Therapeutic agents for the treatment of tuberculosis, especially pulmonary tuberculosis |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RS54761B1 (sr) | 2010-06-24 | 2016-10-31 | Gilead Sciences | Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013096681A1 (en) | 2011-12-22 | 2013-06-27 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
LT2838900T (lt) | 2012-04-17 | 2019-11-11 | Gilead Sciences Inc | Junginiai ir būdai, skirti priešvirusinei terapijai |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
CA2922703A1 (en) * | 2013-08-29 | 2015-03-05 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and body weight related disorders |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP6853782B2 (ja) | 2015-10-22 | 2021-03-31 | 田辺三菱製薬株式会社 | 新規二環性複素環化合物 |
ES2930814T3 (es) * | 2016-05-11 | 2022-12-22 | Guangdong Hebo Pharmaceutical Co Ltd | Inhibidor de péptido deformilasa de anillo espiro de tres miembros o anillo espiro de cinco miembros y uso del mismo como agente antitumoral |
WO2020120576A1 (en) * | 2018-12-11 | 2020-06-18 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | p38α AUTOPHOSPHORYLATION INHIBITORS |
CN109851614B (zh) * | 2019-03-29 | 2023-01-13 | 中山大学 | 一类杂环类肽脱甲酰基酶抑制剂及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0623190B2 (ja) * | 1985-04-16 | 1994-03-30 | サントリー株式会社 | インヒビタ−活性を有するn−アシルピロリジン誘導体及びその製法並びに用途 |
JP2003534239A (ja) * | 1999-12-17 | 2003-11-18 | ヴァージコア・インコーポレーテッド | 新規なスクシナート化合物、組成物、並びに使用及び調製方法 |
ES2283589T3 (es) * | 2001-06-15 | 2007-11-01 | Vicuron Pharmaceuticals, Inc. | Compuestos biciclicos de pirrolidina. |
AR036053A1 (es) * | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
GT200600196A (es) * | 2005-05-23 | 2007-01-15 | Compuestos n-formil de hidroxilamina |
-
2005
- 2005-12-30 SG SG200508608-7A patent/SG133452A1/en unknown
-
2006
- 2006-12-27 AR ARP060105821A patent/AR058769A1/es unknown
- 2006-12-28 AU AU2006334391A patent/AU2006334391A1/en not_active Abandoned
- 2006-12-28 RU RU2008130925/04A patent/RU2008130925A/ru not_active Application Discontinuation
- 2006-12-28 CN CNA2006800494397A patent/CN101346370A/zh active Pending
- 2006-12-28 CA CA002629148A patent/CA2629148A1/en not_active Abandoned
- 2006-12-28 PE PE2006001710A patent/PE20071061A1/es not_active Application Discontinuation
- 2006-12-28 US US12/159,429 patent/US20090318445A1/en not_active Abandoned
- 2006-12-28 BR BRPI0620655-7A patent/BRPI0620655A2/pt not_active IP Right Cessation
- 2006-12-28 JP JP2008547967A patent/JP2009522232A/ja active Pending
- 2006-12-28 KR KR1020087015780A patent/KR20080077655A/ko not_active Application Discontinuation
- 2006-12-28 WO PCT/EP2006/070234 patent/WO2007077186A1/en active Application Filing
- 2006-12-28 EP EP06830830A patent/EP1973898A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20090318445A1 (en) | 2009-12-24 |
WO2007077186A8 (en) | 2007-11-15 |
CN101346370A (zh) | 2009-01-14 |
AU2006334391A1 (en) | 2007-07-12 |
JP2009522232A (ja) | 2009-06-11 |
SG133452A1 (en) | 2007-07-30 |
PE20071061A1 (es) | 2007-12-06 |
BRPI0620655A2 (pt) | 2011-11-22 |
WO2007077186A1 (en) | 2007-07-12 |
KR20080077655A (ko) | 2008-08-25 |
CA2629148A1 (en) | 2007-07-12 |
RU2008130925A (ru) | 2010-02-10 |
EP1973898A1 (en) | 2008-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR051342A1 (es) | Derivados de purina, purinona, deazapurina y deazapurinona como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quina | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
AR065824A1 (es) | Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico. | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
AR064197A1 (es) | Derivados de pirimidina y piridina inhibidores de la proteina quinasa | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR057728A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotropicos. composiciones farmaceuticas. | |
AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
AR053778A1 (es) | Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |